Cancer-associated thromboembolism: could direct-acting oral anticoagulants be a promising therapeutic option? Literature review

[1]Khorana AA et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119:648–655.KhoranaAAIncidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United StatesCancer201311964865510.1002/cncr.2777222893596Search in Google Scholar

[2]Kessler CM. The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009;32: S3–S7KesslerCMThe link between cancer and venous thromboembolism: a reviewAm J Clin Oncol200932S3S710.1097/COC.0b013e3181b01b1719654481Search in Google Scholar

[3]Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160:809–815.HeitJASilversteinMDMohrDNPettersonTMO’FallonWMMeltonLJ3rdRisk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control studyArch Intern Med200016080981510.1001/archinte.160.6.80910737280Search in Google Scholar

[4]Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293:715–722.BlomJWDoggenCJOsantoSRosendaalFRMalignancies, prothrombotic mutations, and the risk of venous thrombosisJAMA200529371572210.1001/jama.293.6.71515701913Search in Google Scholar

[5]Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22:vi85–vi92MandalàMFalangaARoilaFESMO Guidelines Working GroupManagement of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice GuidelinesAnn Oncol201122vi85vi9210.1093/annonc/mdr39221908511Search in Google Scholar

[6]ASCO 2015 Guidelines/VTE. Available at http://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/VTE-Summary-of-Recs.pdfASCO 2015 Guidelines/VTEAvailable at http://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/VTE-Summary-of-Recs.pdfSearch in Google Scholar

[7]With permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer-Associated Venous Thromboembolic Disease V.2.2018 - August 27, 2018. © National Comprehensive Cancer all rights reserved. Accessed 10.12.2018. To view the most recent and complete version of the guideline, go online to WWW.NCCN.orgWith permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer-Associated Venous Thromboembolic Disease V.2.2018 - August 27, 2018. © National Comprehensive Cancer all rights reservedAccessed 10.12.2018. To view the most recent and complete version of the guideline, go online to WWW.NCCN.orgSearch in Google Scholar

[8]National Institute for Health and Care Excellence (2018) Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline (NG89). Available at https://www.nice.org.uk/guidance/ng89. Last accessed December 2018National Institute for Health and Care Excellence2018Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolismNICE guideline (NG89). Available at https://www.nice.org.uk/guidance/ng89. Last accessed December 2018Search in Google Scholar

[9]van Es N, CoppensM, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124(12):1968–1975van EsNCoppensMSchulmanSMiddeldorpSBüllerHRDirect oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trialsBlood2014124121968197510.1182/blood-2014-04-57123224963045Search in Google Scholar

[10]Khorana AA. et al Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720–728KhoranaAARivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with CancerN Engl J Med201938072072810.1056/NEJMoa181463030786186Search in Google Scholar

[11]Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012; 10:807–14.LevineMNGuCLiebmanHAEscalanteCPSolymossSDeitchmanDA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJ Thromb Haemost2012108071410.1111/j.1538-7836.2012.04693.x22409262Search in Google Scholar

[12]Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S et al. Apixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019;94(6):635–640PegourieBKarlinLBenboubkerLOrsini-PiocelleFTiabMAuger-QuittetSApixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot studyAm J Hematol201994663564010.1002/ajh.2545930859608Search in Google Scholar

[13]Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011; 9:653–63.CarrierMLe GalGTayJWuCLeeAYRates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysisJ Thromb Haemost201196536310.1111/j.1538-7836.2011.04215.x21255254Search in Google Scholar

[14]Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–77.GoldhaberSZLeizoroviczAKakkarAKHaasSKMerliGKnabbRMADOPT Trial InvestigatorsApixaban versus enoxaparin for thromboprophylaxis in medically ill patientsN Engl J Med201136521677710.1056/NEJMoa111089922077144Search in Google Scholar

[15]Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D et al. Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy, a 3-Month Interim Analysis. ASH 2018. https://ash.confex.com/ash/2018/webprogram/Paper112577.html (accessed January 14, 2019).CornellRFGoldhaberSZEngelhardtBGMoslehiJJagasiaMPattonDProspective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy, a 3-Month Interim AnalysisASH 2018. https://ash.confex.com/ash/2018/webprogram/Paper112577.html (accessed January 14, 2019).Search in Google Scholar

[16]Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 21; 380:711–719CarrierMAbou-NassarKMallickRTagalakisVShivakumarSSchattnerAApixaban to Prevent Venous Thromboembolism in Patients with CancerN Engl J Med20192138071171910.1056/NEJMoa181446830511879Search in Google Scholar

[17]Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med.2018 15; 378:615–624.RaskobGEvan EsNVerhammePCarrierMDi NisioMGarciaDEdoxaban for the Treatment of Cancer-Associated Venous ThromboembolismN Engl J Med20181537861562410.1056/NEJMoa171194829231094Search in Google Scholar

[18]Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al. Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 10; 36:2017–2023.YoungAMMarshallAThirlwallJChapmanOLokareAHillCComparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)J Clin Oncol201810362017202310.1200/JCO.2018.78.803429746227Search in Google Scholar

[19]McBane II R, Loprinzi CL, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A. et al. Apixaban and Dalteparin in Active Malignancy Associated Venous Thromboembolism. The ADAM VTE Trial. J Thromb Haemost. 2019. [Epub ahead of print]McBaneRIILoprinziCLLe-RademacherJGZemlaTAshraniATafurAApixaban and Dalteparin in Active Malignancy Associated Venous Thromboembolism. The ADAM VTE TrialJ Thromb Haemost2019[Epub ahead of print]10.1111/jth.1466231630479Search in Google Scholar

[20]Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med. 2019; 380(8):781–783AgnelliGDirect Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with CancerN Engl J Med2019380878178310.1056/NEJMe181606030786193Search in Google Scholar

[21]Brunetti ND, Tricarico L, Correale M, De Gennaro L, Santoro F, Ieva R et al. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials. J Thromb Thrombolysis. 2019. [Epub ahead of print]BrunettiNDTricaricoLCorrealeMDe GennaroLSantoroFIevaRDirect oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trialsJ Thromb Thrombolysis2019[Epub ahead of print]10.1007/s11239-019-01974-y31654194Search in Google Scholar